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Abstract
Late diagnosis and treatment may increase morbidity and mortality among persons with
hepatitis C virus (HCV) infection. We included all participants of the Swiss Hepatitis C
Cohort Study (SCCS). We used unadjusted and adjusted logistic and Cox regressions to
determine the association between the geographic origin of the participants and the follow-
ing outcomes: antiviral treatment status; sustained virologic response; cirrhosis at enrol-
ment; incident cirrhosis; loss to follow-up (LTFU); and mortality. The analyses were
adjusted for sex, baseline age, education, source of income, alcohol consumption, injection
drug use (IDU), HCV genotype, HIV or HBV coinfection, duration of HCV infection, time
since enrolment, cirrhosis, (type of) HCV treatment, and centre at enrolment. Among 5,356
persons, 1,752 (32.7%) were foreign-born. IDU was more common among Swiss- (64.1%)
than foreign-born (36.6%) persons. Cirrhosis at enrolment was more frequent among for-
eign- than Swiss-born persons, reflecting the high frequency of cirrhosis among Italian-born
persons who acquired HCV between 1950 and 1970 in Italian healthcare settings. Although
antiviral treatment coverage was similar, the sustained viral response rate was increased
and the mortality was lower among foreign-vs. Swiss-born persons, with the lowest mortality
in persons from Asia/Oceania. LTFU was more frequent in persons from Germany, Eastern
and Southern Europe, and the Americas. In conclusion, in Switzerland, a country with uni-
versal healthcare, geographic origin had no influence on hepatitis C treatment access, and
the better treatment outcomes among foreign-born persons were likely explained by their
lower prevalence of IDU and alcohol consumption than among Swiss-born persons.
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Introduction
Hepatitis C virus (HCV) treatment can induce sustained virologic response that reverses pro-
gression of liver disease and increases life expectancy [1–3]. Access and adherence to treatment
have been associated with socio-demographic factors, including ethnicity [4–6]. Many
resource-rich countries have increasing numbers of residents whose geographic origin differs
from their country of residence. Little is known about access to therapy and therapy outcomes
among patients with hepatitis C in these countries. In Switzerland, foreign-born residents
make up 29.7% of the adult population (Swiss Federal Statistical Office, 2017). Switzerland has
a firm commitment to provide equal access to care for all [7]. The rollout of HCV treatment
offers the opportunity to assess whether Swiss- and foreign-born persons have equal access to
care and treatment, or whether disparities exist.
HCV infections may have affected Swiss- and foreign-born persons by different transmis-
sion pathways and at different times in the person’s life. In Switzerland, the main source of
HCV infection is injection drug use (IDU), which peaked in the 1980s and early 1990s [8,9].
Globally, most HCV infections have been acquired via unsafe medical procedures [10,11]. The
epidemic of HCV infections in Italy and Spain in the years 1950 to 1970 [12–14] became
apparent in Switzerland through an increased HCV prevalence among persons aged 60 or
older who originated from these countries [15]. A previous SCCS study showed that foreign-
born Swiss residents who were employed were more likely to have sustained virologic response
than other groups [16].
We wanted to determine whether foreign-born and Swiss-born HCV-infected persons had
different levels of access to treatment and treatment outcomes, based on data from the large
Swiss Hepatitis C Cohort Study (SCCS).
Methods
Swiss Hepatitis C Cohort Study (SCCS)
The SCCS, established in 2000, includes persons residing in Switzerland and�18 years old
who have anti-HCV antibodies [17]. Study sites include all five university hospitals, three large
non-university hospitals, and some affiliated centres [17]. Data on demographic characteris-
tics, HCV risk factors and genotype, progression of liver disease, HCV treatment, and con-
comitant infections like HBV and HIV are collected by standardized questionnaires that are
completed by physicians or trained study nurses during clinical visits at enrolment and annual
follow-up visits. The ethics committees of all participating centres granted ethical approval for
the study and all participants gave written informed consent.
Eligibility criteria, definitions and statistical analyses
We included everyone registered in the SCCS (up to 10 September 2017) and considered the
following outcomes: a) antiviral treatment status (ATS), indicating if a person was ever treated
for HCV; b) sustained virologic response (SVR); c) cirrhosis at enrolment (CAE; yes/no); d)
incident cirrhosis during follow-up (IC); e) loss to follow-up (LTFU); and f) mortality. Since
some persons LTFU may have died, we also analysed attrition by combining mortality and
LTFU into a single outcome. We defined SVR as an undetectable HCV RNA in serum�12
weeks after treatment end, excluding persons where the viral RNA was only tested less than 12
weeks after treatment end. When we analysed incident cirrhosis, we included only those with-
out cirrhosis at enrolment. People were LTFU if there was no contact for two or more years, so
we only included persons who were enrolled for at least two years before the study closed.
LTFU contained the following dropout categories: moving to a foreign country; wanting to
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discontinue; care continued in a non-SCCS centre; address change without notice; no reply to
written invitations; other. Information on mortality was based on information from the cen-
tres who systematically traced all patients LTFU. No linkage with a death registry was done. If
we did not know the date of death, we used the last date we knew the person was alive.
We used unadjusted and adjusted logistic regression for outcomes a-c, and Cox propor-
tional hazard regression models for time-to-event outcomes d-f. Persons were followed from
enrolment into the cohort until the endpoint occurred or until the most recent follow-up visit.
We censored the study ten years after enrolment into the SCCS because most people had been
followed for less time.
The main exposure of interest was geographic origin of the persons; we used country of
birth as a proxy of origin and divided the participants into Swiss-born and foreign-born. In a
second analysis, we divided participants into groups of at least 100 members, based on the UN
classification for geographic regions [18]: Switzerland, Germany, Italy, Portugal, Southern
Europe (except Italy and Portugal), Eastern Europe, Western and Northern Europe (except
Germany), Asia and Oceania, Africa, and the Americas (North- and South America
combined).
For the adjusted models, we included explanatory variables documented at enrolment into
the SCCS: sex; age (18–40, 41–60,�61 years); centre (Basel, Bern, Geneva, Lausanne, Lugano,
Neuchaˆtel, St. Gallen, Zu¨rich); highest level of education (low, middle, high; provided by the
Swiss Conference of Cantonal Ministers of Education [19]); source of income (working, retire-
ment pension or social assistance, unemployed); IDU (never, former, current); past and pres-
ent alcohol consumption (light [<20g/day], moderate [20-40g/day], excessive [>40 g/day],
former drinker [reported to have drunk >40 g/day]); time between HCV diagnosis and enrol-
ment into the cohort (<2, 2–5, 6–10,>10 years); calendar year of enrolment (2000–2003,
2004–2007, 2008–2011, 2012–2017); HCV genotype (1, 2, 3, 4; genotypes 5 and 6 were very
rare and set to missing); and HIV and/or HBV coinfection. We considered cirrhosis at enrol-
ment (yes/no) as a covariate in all analyses except for cirrhosis at enrolment and incident cir-
rhosis. The type of treatment—or absence of it—could also influence the outcomes. We
therefore adjusted the models on SVR, incident cirrhosis, mortality, LTFU and treatment (not
treated, treated with direct-acting antivirals [DAA], treated with non-DAA regimens). Since
SVR was only analysed in treated persons, we adjusted this analysis only for type of treatment
(DAA versus non-DAA) and considered only treatments before the event of interest.
Our first analysis combined all foreign-born persons into one group. Our second analysis
grouped people into the geographic units described above. We performed a main analysis, and
two sensitivity analyses where we either imputed or excluded missing values. In the main anal-
ysis, we assumed HBV and HIV status were negative if missing. We used multiple imputation
by chained equations (MICE package for R [20]) to impute missing values. Because adding
variables that are not part of the analysis can improve imputation [21], we added body weight,
diabetes comorbidity, and a binary indicator for pre-treatment before cohort enrolment. We
also included the outcome of interest. We ran the models on 20 imputed datasets for each anal-
ysis and used Rubin’s rule to pool the estimates. All analyses were performed with R version
3.3.3 (R core team, 2016).
Results
We included 5,356 persons enrolled into the SCCS. The majority were male (62.3%), and the
median age at enrolment was 45.3 years (Table 1).
Most were current (39.5%) or former (15.6%) IDU; 29.5% reported past or current exces-
sive alcohol use. At enrolment, few had HIV or HBV coinfections (HIV: 67.5% negative and
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Table 1. Baseline characteristics (including test for difference in proportions) of the Swiss Hepatitis C Cohort Study participants, by geographic origin.
Switzer-
land
All foreign
born
Germany Italy Portugal Eastern
Europe
Southern
Europe
Western
Europe
Asia and
Oceania
Africa America N
N 3604
(67.3)
1752
(32.7)
121 (2.3) 546 (10.2) 119 (2.2) 129 (2.4) 202 (3.8) 220 (4.1) 155 (2.9) 160 (3) 100 (1.9) 5356
Gender P = 0.018 P = 0.13 P = 0.066 P = 0.008 P < 0.001 P = 0.85 P < 0.001 P = 0.72 P = 0.2 P = 0.043
Female 1318
(36.6)
700 (40) 53 (43.8) 177 (32.4) 29 (24.4) 90 (69.8) 72 (35.6) 111 (50.5) 54 (34.8) 67 (41.9) 47 (47) 2018
(37.7)
Male 2286
(63.4)
1052 (60) 68 (56.2) 369 (67.6) 90 (75.6) 39 (30.2) 130 (64.4) 109 (49.5) 101 (65.2) 93 (58.1) 53 (53) 3338
(62.3)
Age (years) P < 0.001 P = 0.11 P < 0.001 P = 0.002 P = 0.016 P = 0.48 P = 0.007 P = 0.002 P = 0.21 P = 0.77
18–40 1347
(37.4)
545 (31.1) 35 (28.9) 96 (17.6) 50 (42) 61 (47.3) 77 (38.1) 64 (29.1) 79 (51) 49 (30.6) 34 (34) 1892
(35.3)
41–60 1859
(51.6)
870 (49.7) 68 (56.2) 262 (48) 67 (56.3) 50 (38.8) 98 (48.5) 120 (54.5) 60 (38.7) 91 (56.9) 54 (54) 2729
(51)
� 61 391
(10.8)
335 (19.1) 18 (14.9) 187 (34.2) 1 (0.8) 18 (14) 27 (13.4) 36 (16.4) 16 (10.3) 20 (12.5) 12 (12) 726
(13.6)
Unknown 7 (0.2) 2 (0.1) 0 (0.0) 1 (0.2) 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 9 (0.2)
Education P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P = 0.006 P < 0.001 P < 0.001 P < 0.001
Low 650 (18) 503 (28.7) 15 (12.4) 188 (34.4) 68 (57.1) 15 (11.6) 60 (29.7) 34 (15.5) 57 (36.8) 38 (23.8) 28 (28) 1153
(21.5)
Middle 2318
(64.3)
851 (48.6) 62 (51.2) 273 (50.2) 45 (37.8) 49 (38) 115 (56.9) 131 (59.5) 61 (39.4) 76 (47.5) 38 (38) 3169
(59.2)
High 581
(16.1)
366 (20.9) 42 (34.7) 74 (13.6) 4 (3.4) 62 (48.1) 26 (12.9) 54 (24.5) 32 (20.6) 40 (25) 32 (32) 947
(17.7)
Unknown 55 (1.5) 32 (1.8) 10 (1.8) 10 (1.8) 2 (1.7) 3 (2.3) 1 (0.5) 1 (0.5) 5 (3.2) 6 (3.8) 2 (2) 87
(1.6)
Employm. P = 0.002 P = 0.008 P < 0.001 P = 0.027 P < 0.001 P = 0.63 P = 0.13 P = 0.003 P = 0.74 P = 0.043
Unempl. 381
(10.6)
145 (8.3) 9 (7.4) 25 (4.6) 11 (9.2) 17 (13.2) 17 (8.4) 15 (6.8) 26 (16.8) 19 (11.9) 6 (6) 526
(9.8)
Working 2074
(57.5)
1084
(61.9)
87 (71.9) 304 (55.7) 83 (69.7) 93 (72.1) 119 (58.9) 139 (63.2) 97 (62.6) 92 (57.5) 70 (70) 3158
(59)
Inval. 1136
(31.5)
512 (29.2) 25 (20.7) 213 (39) 25 (21) 19 (14.7) 62 (30.7) 66 (30) 32 (20.6) 46 (28.7) 24 (24) 1648
(30.8)
Unknown 13 (0.4) 11 (0.6) 0 (0.0) 4 (0.7) 0 (0.0) 0 (0.0) 4 (2) 0 (0.0) 0 (0.0) 3 (1.9) 0 (0.0) 24
(0.4)
(History
of)
injection
drug use
P < 0.001 P < 0.001 P < 0.001 P = 0.26 P < 0.001 P < 0.001 P = 0.012 P < 0.001 P < 0.001 P < 0.001
Not user 1254
(34.8)
1098
(62.7)
68 (56.2) 357 (65.4) 49 (41.2) 107 (82.9) 125 (61.9) 98 (44.5) 106 (68.4) 127
(79.4)
61 (61) 2352
(43.9)
Former 620
(17.2)
214 (12.2) 18 (14.9) 81 (14.8) 21 (17.6) 10 (7.8) 21 (10.4) 29 (13.2) 15 (9.7) 8 (5) 11 (11) 834
(15.6)
Current 1691
(46.9)
427 (24.4) 35 (28.9) 105 (19.2) 47 (39.5) 12 (9.3) 56 (27.7) 91 (41.4) 31 (20) 22 (13.8) 28 (28) 2118
(39.5)
Unknown 39 (1.1) 13 (0.7) 0 (0.0) 3 (0.5) 2 (1.7) 0 (0.0) 0 (0.0) 2 (0.9) 3 (1.9) 3 (1.9) 0 (0) 52 (1)
Alcohol
cons.
P < 0.001 P = 0.44 P < 0.001 P = 0.091 P < 0.001 P < 0.001 P = 0.43 P < 0.001 P < 0.001 P = 0.29
Light 1791
(49.7)
1037
(59.3)
62 (51.2) 333 (61) 49 (41.2) 90 (69.8) 131 (64.9) 103 (46.8) 100 (64.5) 114
(71.2)
55 (55) 2828
(52.8)
Moderate 618
(17.1)
313 (17.9) 26 (21.5) 98 (17.9) 30 (25.2) 22 (17.1) 30 (14.9) 41 (18.6) 26 (16.8) 20 (12.5) 20 (20) 931
(17.4)
Excessive 915
(25.4)
309 (17.6) 27 (22.3) 81 (14.8) 32 (26.9) 12 (9.3) 34 (16.8) 64 (29.1) 23 (14.8) 19 (11.9) 17 (17) 1224
(22.9)
Former 265 (7.4) 87 (5) 6 (5) 32 (5.9) 7 (5.9) 5 (3.9) 7 (3.5) 12 (5.5) 4 (2.6) 7 (4.4) 7 (7) 352
(6.6)
Unknown 15 (0.4) 6 (0.3) 0 (0.0) 2 (0.4) 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.3) 0 (0.0) 1 (1) 21
(0.4)
(Continued)
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Table 1. (Continued)
Switzer-
land
All foreign
born
Germany Italy Portugal Eastern
Europe
Southern
Europe
Western
Europe
Asia and
Oceania
Africa America N
From
diagnosis
to enrolm.
(years)
P = 0.0014 P = 0.098 P = 0.48 P = 0.062 P = 0.45 P = 0.46 P = 0.14 P < 0.001 P = 0.015 P = 0.33
0–2 1303
(36.2)
725 (41.4) 50 (41.3) 203 (37.2) 55 (46.2) 54 (41.9) 82 (40.6) 93 (42.3) 77 (49.7) 71 (44.4) 40 (40) 2028
(37.9)
2–6 839
(23.3)
386 (22) 21 (17.4) 118 (21.6) 26 (21.8) 33 (25.6) 44 (21.8) 50 (22.7) 28 (18.1) 37 (23.1) 29 (29) 1225
(22.9)
6–10 613 (17) 284 (16.2) 14 (11.6) 82 (15) 20 (16.8) 18 (14) 35 (17.3) 40 (18.2) 31 (20) 31 (19.4) 13 (13) 897
(16.7)
> 10 762
(21.1)
315 (18) 32 (26.4) 125 (22.9) 15 (12.6) 23 (17.8) 35 (17.3) 34 (15.5) 16 (10.3) 18 (11.2) 17 (17) 1077
(20.1)
Calendar
year of
enrolm.
P = 0.054 P < 0.001 P = 0.0035 P = 0.002 P = 0.002 P = 0.34 P = 0.27 P = 0.091 P = 0.39 P = 0.7
2000–03 1431
(39.7)
647 (36.9) 39 (32.2) 230 (42.1) 32 (26.9) 40 (31) 74 (36.6) 92 (41.8) 46 (29.7) 53 (33.1) 41 (41) 2078
(38.8)
2004–07 953
(26.4)
449 (25.6) 34 (28.1) 107 (19.6) 30 (25.2) 25 (19.4) 64 (31.7) 67 (30.5) 50 (32.3) 49 (29.4) 23 (23) 1402
(26.2)
2008–11 358 (9.9) 204 (11.6) 26 (21.5) 53 (9.7) 22 (18.5) 16 (12.4) 22 (10.9) 19 (8.6) 17 (11) 16 (10) 13 (13) 562
(10.5)
2012–17 862
(23.9)
452 (25.8) 22 (18.2) 156 (28.6) 35 (29.4) 48 (37.2) 42 (20.8) 42 (19.1) 42 (27.1) 42 (26.2) 23 (23) 1314
(24.5)
HCV
genotype
P < 0.001 P = 0.62 P < 0.001 P = 0.086 P < 0.001 P < 0.001 P = 0.15 P = 0.53 P < 0.001 P < 0.001
1 1592
(44.2)
849 (48.5) 64 (52.9) 246 (45.1) 61 (51.3) 86 (66.7) 114 (56.5) 97 (44.1) 68 (43.9) 47 (29.4) 66 (66) 2441
(45.6)
2 229 (6.4) 169 (9.6) 8 (6.6) 87 (15.9) 2 (1.7) 4 (3.1) 15 (7.49 23 (10.5) 11 (7.1) 12 (7.5) 7 (7) 398
(7.4)
3 985
(27.3)
324 (18.5) 33 (27.3) 87 (15.9) 28 (23.5) 20 (15.5) 30 (14.9) 56 (25.5) 43 (27.7) 16 (10) 11 (11) 1309
(24.4)
4 311 (8.6) 172 (9.8) 8 (6.6) 38 (7) 13 (10.9) 3 (2.3) 19 (9.4) 21 (9.5) 8 (5.2) 57 (35.6) 5 (5) 483 (9)
Unknown 487
(13.5)
238 (13.6) 8 (6.6) 88 (16.1) 15 (12.6) 16 (12.4) 24 (11.9) 23 (10.5) 25 (16.1) 28 (17.5) 11 (11) 725
(13.5)
HIV status P < 0.001 P = 0.57 P = 0.047 P = 0.68 P = 0.023 P = 0.8 P = 0.32 P = 0.34 P = 0.22 P = 0.096
Negative 2450
(68)
1167
(66.6)
84 (69.4) 321 (58.8) 90 (75.6) 82 (63.6) 138 (68.4) 160 (72.7) 98 (63.2) 122
(76.2)
72 (72) 3617
(67.5)
Positive 241 (6.7) 71 (4.1) 6 (5) 19 (3.5) 7 (5.9) 1 (0.8) 12 (5.9) 11 (5) 6 (3.9) 7 (4.4) 2 (2) 312
(5.8)
Unknown 913
(25.3)
514 (29.3) 31 (25.6) 206 (37.7) 22 (18.5) 46 (35.7) 52 (25.7) 49 (22.3) 51 (32.9) 31 (19.4) 26 (26) 1427
(26.6)
Chronic
HBV
infection
P = 0.5 P = 0.84 P = 0.99 P = 1 P = 0.75 P = 0.69 P = 0.58 P = 0.026 P = 0.023 P = 1
Negative 2772
(76.9)
1324
(75.6)
86 (71.1) 401 (73.4) 93 (78.2) 96 (73.6) 157 (77.8) 173 (78.6) 123 (79.4) 121
(75.6)
75 (75) 4096
(76.5)
Positive 58 (1.6) 33 (1.9) 1 (0.8) 9 (1.6) 2 (1.7) 1 (0.8) 2 (1) 2 (0.9) 7 (4.5) 7 (4.4) 2 (2) 91
(1.7)
Unknown 774
(21.5)
395 (22.5) 34 (28.1) 136 (24.9) 24 (20.2) 33 (25.6) 43 (21.3) 45 (20.5) 25 (16.1) 32 (20) 23 (23) 1169
(21.8)
(Continued)
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26.6% missing; HBV: 76.5% negative and 21.8% missing) and most had no cirrhosis (82.7%).
Participants were followed for up to 16.6 years (median follow-up duration 7.2 years). Swiss-
born participants made up 67.3% of the population, 32.7% were foreign-born (Table 1). Fig 1
shows a flowchart of persons included in the unadjusted and adjusted regression analyses (Fig
1). The number of persons we excluded from the unadjusted analyses varied from 0 (“antiviral
treatment status”) to more than 800 people (“response to antivirals”, “incident cirrhosis”). In
the adjusted analyses, we excluded between 319–970 persons because of missing values in
covariates. S1 Table shows the coefficients for the unadjusted and adjusted models in Figs 2–4.
The results of the differences in proportions of each characteristic across the geographic
groups are shown in Table 1.
Comparison of Swiss-born and foreign-born persons
Results of the unadjusted and adjusted analyses are shown in Fig 2. In unadjusted analyses (Fig
2, left panel), foreign-born persons were more likely to have cirrhosis at enrolment (odds ratio
[OR], 1.30; 95% confidence interval [CI], 1.12–1.51) and to have ever been on antiviral therapy
(OR 1.23; 95% CI, 1.09–1.39) than Swiss-born persons. LTFU was higher (hazard ratio [HR]
1.16; 95% CI 1.04–1.31) and mortality was lower (HR 0.80; 95% CI 0.65–0.97) in foreign- than
in Swiss-born persons.
Table 1. (Continued)
Switzer-
land
All foreign
born
Germany Italy Portugal Eastern
Europe
Southern
Europe
Western
Europe
Asia and
Oceania
Africa America N
Enrolm.
centre
P < 0.001 P < 0.001 P < 0.001 P < 0.001 P = 0.006 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P = 0.0015
Basel 234 (6.5) 118 (6.7) 20 (16.5) 37 (6.8) 4 (3.4) 10 (7.8) 13 (6.4) 10 (4.5) 10 (4.5) 7 (4.4) 6 (6) 352
(6.6)
Bern 752
(20.9)
253 (14.4) 20 (16.5) 64 (11.7) 18 (15.1) 24 (18.6) 30 (14.9) 19 (8.6) 19 (8.6) 26 (16.2) 16 (16) 1005
(18.8)
Geneva 149 (4.1) 154 (8.8) 2 (1) 36 (6.6) 13 (10.9) 8 (6.2) 26 (12.9) 33 (15) 33 (15) 24 (15) 6 (6) 303
(5.7)
Lausanne 165 (4.6) 106 (6.1) 3 (2.5) 24 (4.4) 18 (15.1) 5 (3.9) 9 (4.5) 17 (7.7) 17 (7.7) 12 (7.5) 13 (13) 271
(5.1)
Lugano 387
(10.7)
252 (14.4) 3 (2.5) 187 (34.3) 3 (2.5) 12 (9.3) 12 (5.9) 9 (4.1) 9 (4.1) 11 (6.9) 11 (11) 639
(11.9)
Neuchaˆtel 247 (6.9) 159 (9.1) 1 (0.8) 30 (5.5) 28 (23.5) 7 (5.4) 12 (5.9) 36 (16.4) 36 (16.4) 31 (19.4) 7 (7) 406
(7.6)
St. Gallen 716
(19.9)
225 (12.8) 20 (16.5) 53 (9.7) 12 (10.1) 11 (8.5) 34 (16.8) 52 (23.6) 52 (23.6) 14 (8.8) 9 (9) 941
(17.6)
Zu¨rich 954
(26.5)
485 (27.7) 52 (43) 115 (21.1) 23 (19.3) 52 (40.3) 66 (32.7) 44 (20) 44 (20) 35 (21.9) 32 (32) 1439
(26.9)
Cirrhotic at
enrolm.
P < 0.001 P = 0.2 P < 0.001 P = 1 P = 0.44 P = 0.82 P = 0.58 P = 0.63 P = 0.89 P = 0.62
No 3026
(84)
1402 (80) 96 (79.3) 393 (72) 97 (81.5) 113 (87.6) 166 (82.2) 189 (85.9) 126 (81.3) 135
(84.4)
87 (87) 4428
(82.7)
Yes 547
(15.2)
330 (18.8) 24 (19.8) 149 (27.3) 17 (14.3) 16 (12.4) 32 (15.8) 30 (13.6) 26 (16.8) 23 (14.4) 13 (13) 877
(16.49)
Unknown 31 (0.9) 20 (1.1) 1 (0.8) 4 (0.7) 5 (4.2) 0 (0.0) 4 (2) 1 (0.5) 3 (1.9) 2 (1.2) 0 (0.0) 51 (1)
Employm. = employment; inval. = invalid pension, social support. Education reflects the highest level of education reached (Swiss Conference of Cantonal Ministers of
Education, 2017). Alcohol cons. (= consumption): no or light:� grams of alcohol per day; moderate: >20–40; excessive: >40; former> 40 before enrolment. Southern
Europe = Southern Europe except Italy and Portugal, Western Europe = Western and Northern Europe except Germany, America = North and South America
combined. P-values (based on Chi-square tests) show difference in proportion between the Swiss group and the group of considered geographic origin.
https://doi.org/10.1371/journal.pone.0218706.t001
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Fig 1. Selection of the Swiss Hepatitis C Cohort Study participants included in the unadjusted and adjusted analyses.
https://doi.org/10.1371/journal.pone.0218706.g001
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The adjusted analyses confirmed the higher rates of SVR (OR 1.29; 95% CI 1.02–1.65), of
cirrhosis at enrollment (OR 1.29; 95% CI 1.06–1.56), and of LTFU (OR 1.34; 95% CI 1.17–
1.54) among foreign-born persons (Fig 2, right panel). Mortality was lower among foreign-
than Swiss-born persons (OR 0.71; 0.56–0.90). Contrary to the unadjusted analysis, there was
no longer a difference in antiviral treatment uptake. When we combined loss to follow-up and
mortality into a single attrition outcome, results were similar for foreign- and Swiss- born per-
sons both in the unadjusted and adjusted analyses (Fig 2).
Foreign-born persons LTFU had less often (a history of) IDU than persons not LTFU,
while the opposite applied to Swiss-born persons LTFU. Foreign- and Swiss-born persons
LTFU were younger and less frequently cirrhotic than persons not LTFU (S2 Table).
Comparison of different countries and regions
When we compared persons from each region or country to Swiss-born persons, some notable
differences emerged. Italian-born participants were more likely to have cirrhosis at enrolment in
both the unadjusted and adjusted analyses (Fig 3, panels A), they had more incident cirrhosis dur-
ing follow-up in the unadjusted analysis (Fig 3, panels B), and they were more likely to be treated
than Swiss-born participants in the unadjusted, but not in the adjusted analysis (adjusted OR
1.28; 95% CI 0.99–1.66) (Fig 3, panels C). In the adjusted analysis, persons from Asia/Oceania and
Southern Europe were more likely to have SVR than Swiss-born participants (Fig 3, panels D).
In both the unadjusted and adjusted analyses, mortality was lower in those from Asia/Ocea-
nia than in people of Swiss origin (Fig 4, panels A). LTFU was higher in both the unadjusted
and adjusted analyses in people from Germany (HR 1.74; 95% CI 1.23–2.47), Eastern Europe
(HR 1.96; 95% CI 1.37–2.8), Southern Europe (HR 1.58; 95% CI 1.18–2.13) and the Americas
(HR 1.81; 95% CI 1.23–2.67) (all data are from the adjusted analysis, Fig 4, panels B, right).
Attrition was similar between Swiss- and foreign-born persons from all countries or regions in
the unadjusted analysis and, in the adjusted analysis, higher for those from Eastern and South-
ern Europe and the Americas (Fig 4, panels C).
Results from the sensitivity analyses, where we either replaced missing values with multiple
imputations or removed persons with missing values, were similar to the main analyses (S3
Table).
Fig 2. Comparison of Swiss- and foreign-born persons for all analyses. Unadjusted (left) and adjusted (right) logistic and Cox regression
analyses for different outcomes of Swiss-born persons (= reference) and foreign-born persons in the Swiss Hepatitis C Cohort Study. Odds
ratios (OR; with 95% confidence intervals) are shown for antiviral treatment status (ATS), sustained virologic response (SVR) and cirrhosis at
enrolment (CAE). Hazard ratios (HR) are shown for incident cirrhosis (IC), loss to follow-up (LTFU), mortality and attrition.
https://doi.org/10.1371/journal.pone.0218706.g002
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Fig 3. Comparison of persons by geographic origin: cirrhosis and treatment (outcomes). Unadjusted and adjusted logistic
and Cox regression analyses by geographic origin of the Swiss Hepatitis C Cohort Study participants. The following outcomes
are shown: cirrhosis at enrolment (A), incident cirrhosis (B), antiviral treatment status (C), and sustained virologic response
(SVR) (D). Odds ratios, hazard ratios and 95% confidence intervals are presented. Missing HIV and HBV values were assumed
to be negative.
https://doi.org/10.1371/journal.pone.0218706.g003
Impact of geographic origin in the Swiss Hepatitis C Cohort Study
PLOS ONE | https://doi.org/10.1371/journal.pone.0218706 June 24, 2019 9 / 15
Discussion
We found that geographic origin did not influence access to antiviral treatment for HCV-
infected patients enrolled in the SCCS. We did find a few notable differences between foreign-
born and Swiss-born persons: although cirrhosis at enrolment was higher among foreign-
than Swiss-born persons, the higher SVR probably lowered mortality among foreign-born per-
sons. LTFU varied substantially between groups of different origin.
Fig 4. Comparison of persons by geographic origin: mortality, loss to follow-up and attrition. Unadjusted and adjusted Cox
regression analyses by geographic origin of the Swiss Hepatitis C Cohort Study participants. The following outcomes are shown:
mortality (A), loss to follow-up (B) and attrition (C). Hazard ratios and 95% confidence intervals are presented. Missing HIV and
HBV values were assumed to be negative.
https://doi.org/10.1371/journal.pone.0218706.g004
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Cirrhosis at enrolment
The higher prevalence of cirrhosis at enrolment among foreign-born participants was the
result of the high prevalence of cirrhosis at enrolment among persons from Italy, the largest
group of foreign-born people in Switzerland (Swiss Federal Statistical Office 2017) and in the
SCCS (Table 1). Many Italian-born persons had acquired HCV in Italian healthcare settings
between 1950 and 1970 [12,13]. These people were often diagnosed long after they were
infected with HCV [15] and tended to be older than Swiss-born people with HCV, which
increased their risk of presenting with cirrhosis [15].
Antiviral treatment status, SVR and incident cirrhosis
The fact that there are no differences in antiviral treatment status and incident cirrhosis
between Swiss- born and foreign-born persons is reassuring. Even though foreign-born per-
sons may have faced obstacles including language problems or cultural differences, these did
not negatively affect the uptake of HCV therapy. In the comparison of different countries and
regions, antiviral treatment coverage was higher in Italian-born persons than in all other
groups including Swiss-born persons, but that difference disappeared in the adjusted analysis.
Many Italian-born residents of Switzerland live in the Italian-speaking canton of Ticino close
to the Italian border. In Ticino, efforts to find HCV-infected Italian-born persons have been
ongoing for many years, with the involvement of general practitioners. HCV treatment in
Ticino is decentralized into smaller facilities, which may have facilitated earlier access to ther-
apy and improved therapy coverage. The high prevalence of cirrhosis at enrolment in this pop-
ulation further encouraged early treatment, including treatment with DAA.
The higher SVR among foreign-born persons in the adjusted analysis, despite their higher
proportion of cirrhosis, may be a consequence of the lower prevalence of IDU and of less alco-
hol consumption among foreign-born persons (Table 1). Although Switzerland offers a wide
range of treatment options for people with (a history of) IDU [22], there are still some gaps in
the treatment cascade [22–24], and these may have lowered the rate of treatment and of SVR
among persons with (a history of) IDU in Switzerland.
To our knowledge, there are no previous publications from Europe on the impact of geo-
graphic origin on access to treatment and treatment outcomes in persons born in the respec-
tive country compared to foreign-born persons. In the US, having a health insurance was
associated with improved access to HCV care [25,26], and disparities in access to health insur-
ance have been observed among ethnic minority groups [26]. In contrast, our data from a
country with equal access to healthcare for all residents show that similar outcomes can be
achieved, irrespective of country of origin. This is relevant, as the proportion of HCV-infected
foreign-born persons among all HCV infections is up to one third in European countries and
in the US [27,28], and may be similarly high in other resource-rich countries. These good out-
comes for foreign-born persons with HCV infection should be achievable not only in countries
with universal healthcare and predominantly European migrants (e.g. Switzerland) [15], but
also in countries with universal healthcare and many non-European migrants (e.g. the Nether-
lands and the UK) [15]. This would follow the example of Canada, where similar access to
treatment and similar treatment outcomes were recently shown for Canadian- and foreign-
born persons from highly diverse countries of origin [29].
Loss to follow-up
Higher LTFU among foreign-born persons was driven by immigrants from Eastern and
Southern Europe, the Americas, and Germany and probably reflects migration patterns in
Switzerland, since many persons from these countries come to Switzerland for employment
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and then return to their home countries [30]. These persons are recommended to continue
HCV care in their home countries. Differences in LTFU may also be caused by center-specific
factors, including variable resources for tracing patients.
Among foreign-born persons LTFU, there may be persons who emigrated and died in their
country of destination. However, numbers are likely low, as only 39 foreign-born persons
LTFU were older than 60 years, and foreign-born persons LTFU were less frequently cirrhotic
at enrolment than persons not LTFU (S2 Table).
Mortality
The higher prevalence of cirrhosis at enrolment among many Italian-born residents did not
increase mortality (Fig 4).This is likely the result of their good treatment coverage, although
the better coverage in the unadjusted analysis disappeared in the adjusted analysis (Fig 3).
Although Swiss-born persons were generally younger than foreign-born persons, they did not
live longer, perhaps because they were more likely to have a history of IDU. For IDU, the prob-
ability of being treated is often influenced by psychosocial and socio-economic problems
[31,32], and by increased alcohol consumption [33]. Although our multivariable models
accounted for IDU, we could not adjust for intensity of drug use, and we had no information
on other associated lifestyle factors like dietary habits, physical activity, and smoking behav-
iour. Only 5.8% of the persons in our study population were HIV-positive, but HIV infection,
a risk factor for accelerated HCV disease progression, was also more frequent among Swiss-
born persons (6.7% vs. 4.1%).
It is difficult to estimate the contribution of the “healthy migrant effect”. This effect has
been shown in the European Union (EU), where out of 10 anti-HCV prevalence estimates
among the general migrant population, 70% were comparable to the in-country prevalence
and 30% were lower [34]. In Switzerland, this effect may be counterbalanced by the high num-
ber of migrants from Italy, the EU country with the highest prevalence of HCV infections [35].
Strengths and limitations
Our study was strengthened by the large number of persons enrolled into the cohort, and the
long follow-up period. Agreement between complete case analysis results and imputed analysis
results supports the validity of our findings. Most differences in outcomes were caused by vari-
ation in the size of the confidence intervals and reflect differences in sample size rather than
effect size.
Our study may be limited in its generalizability for three reasons. First, Switzerland has a
predominantly European migration pattern [9]. Second, most groups of foreign-born people
were small, which limited the power of our analysis. To reach a reasonable sample size we had
to group people from culturally diverse regions (e.g., “Asia/Oceania” includes people from
Eastern Asian and Arab countries). Third, SCCS participants are likely to be in a more
advanced stage of the disease than HCV-infected persons in the general Swiss population [17].
Conclusions
We found that in Switzerland, a country with universal healthcare, geographic origin had no
influence on access to hepatitis C treatment. Foreign-born persons had more frequent SVR
and lower mortality despite more frequent cirrhosis at enrolment, and they were more often
LTFU. The high frequency of cirrhosis at enrolment among foreign-borns mirrors the high
rate of cirrhosis at enrolment among Italian-born persons who have acquired HCV between
1950 and 1970 in Italian healthcare settings. However since most of the Italian-born persons
were treated, mortality was not increased. The better treatment outcomes among foreign-born
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persons were likely explained by their lower prevalence of IDU and of alcohol consumption
than among Swiss-born persons.
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